Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE ) (FORCE)
Primary Purpose
COVID
Status
Completed
Phase
Phase 2
Locations
France
Study Type
Interventional
Intervention
avdoralimab
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for COVID
Eligibility Criteria
Inclusion Criteria:
- COVID-19 severe pneumonia patients need for oxygen therapy ≥ 5 l/min or high-flow oxygen therapy
- COVID-19 related Acute Respiratory Distress Syndrome (ARDS) requiring mechanical ventilation
Exclusion Criteria:
- Pregnant woman
- Uncontrolled sepsis of bacterial or fungal origin
Sites / Locations
- Assistance Publique Hôpitaux de Marseille
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
avdoralimab
Placebo
Arm Description
Biological/Vaccine: avdoralimab intravenous administration of avdoralimab Other Names: • IPH5401
intravenous administration of Placebo
Outcomes
Primary Outcome Measures
Clinical improvement using WHO ordinal scale
improvement of WHO ordinal scale
Number of ventilator-free days at Day 28 (VFD28)
Number of days without mechanical ventilation at Day 28 for COVID-19 related Acute Respiratory Distress Syndrome (ARDS) Patients hospitalized in ICU
Secondary Outcome Measures
Number of participants with treatment-related adverse events
Full Information
NCT ID
NCT04371367
First Posted
April 29, 2020
Last Updated
May 26, 2021
Sponsor
Assistance Publique Hopitaux De Marseille
Collaborators
Innate Pharma
1. Study Identification
Unique Protocol Identification Number
NCT04371367
Brief Title
Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE )
Acronym
FORCE
Official Title
A Double-blind, Randomized Study Versus Placebo of Avdoralimab (IPH5401), an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia
Study Type
Interventional
2. Study Status
Record Verification Date
May 2021
Overall Recruitment Status
Completed
Study Start Date
April 27, 2020 (Actual)
Primary Completion Date
March 30, 2021 (Actual)
Study Completion Date
March 30, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique Hopitaux De Marseille
Collaborators
Innate Pharma
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The primary objective of this trial is to improve the proportion of COVID-19 patients with severe pneumonia who no longer need to be hospitalized, and to reduce the need for and duration of mechanical ventilation in patients with COVID-19 pneumonia complicated by acute respiratory distress syndrome (ARDS).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
COVID
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
Parallel Assignment
Masking
ParticipantInvestigator
Masking Description
Double (Participant, Investigator)
Allocation
Randomized
Enrollment
208 (Actual)
8. Arms, Groups, and Interventions
Arm Title
avdoralimab
Arm Type
Experimental
Arm Description
Biological/Vaccine: avdoralimab intravenous administration of avdoralimab
Other Names:
• IPH5401
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
intravenous administration of Placebo
Intervention Type
Biological
Intervention Name(s)
avdoralimab
Other Intervention Name(s)
IPH5401
Intervention Description
intravenous administration of avdoralimab
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
intravenous administration of placebo
Primary Outcome Measure Information:
Title
Clinical improvement using WHO ordinal scale
Description
improvement of WHO ordinal scale
Time Frame
day 28
Title
Number of ventilator-free days at Day 28 (VFD28)
Description
Number of days without mechanical ventilation at Day 28 for COVID-19 related Acute Respiratory Distress Syndrome (ARDS) Patients hospitalized in ICU
Time Frame
day 28
Secondary Outcome Measure Information:
Title
Number of participants with treatment-related adverse events
Time Frame
day 28
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
COVID-19 severe pneumonia patients need for oxygen therapy ≥ 5 l/min or high-flow oxygen therapy
COVID-19 related Acute Respiratory Distress Syndrome (ARDS) requiring mechanical ventilation
Exclusion Criteria:
Pregnant woman
Uncontrolled sepsis of bacterial or fungal origin
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Emilie Garrido-Pradalie
Organizational Affiliation
Assistance Publique Hôpitaux de Marseille
Official's Role
Study Director
Facility Information:
Facility Name
Assistance Publique Hôpitaux de Marseille
City
Marseille
ZIP/Postal Code
13354
Country
France
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
36218354
Citation
Carvelli J, Meziani F, Dellamonica J, Cordier PY, Allardet-Servent J, Fraisse M, Velly L, Barbar SD, Lehingue S, Guervilly C, Desgrouas M, Camou F, Piperoglou C, Vely F, Demaria O, Karakunnel J, Fares J, Batista L, Rotolo F, Viotti J, Boyer-Chammard A, Lacombe K, Le Dault E, Carles M, Schleinitz N, Vivier E; FOR COVID Elimination (FORCE) Study Group. Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE]). Crit Care Med. 2022 Dec 1;50(12):1788-1798. doi: 10.1097/CCM.0000000000005683. Epub 2022 Oct 10.
Results Reference
derived
PubMed Identifier
34473343
Citation
Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2.
Results Reference
derived
Learn more about this trial
Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE )
We'll reach out to this number within 24 hrs